Prothena Corporation plc

PRTA.US
Healthcare · Biotechnology
8.56
-0.14 (-1.61%)
USD · NASDAQ

Company Information

Company Name
Prothena Corporation plc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: USG728001086
CIK: 0001559053
CUSIP: G72800108
Currency: USD
Full Time Employees: 67
Phone: 353 1 236 2500
Fiscal Year End: December
IPO Date: Dec 21, 2012
Description:

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Address:

77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

People

Directors & Officers

Name Title Year Born
Dr. Gene G. Kinney Ph.D. President, CEO & Director 1969
Mr. Tran B. Nguyen M.B.A. Chief Financial Officer 1974
Mr. Brandon S. Smith Chief Operating Officer 1975
Dr. Wagner M. Zago Ph.D. Chief Scientific Officer 1973
Dr. Chad H. Swanson Ph.D. Chief Development Officer NA
Ms. Karin L. Walker CPA Chief Accounting Officer & Controller 1963
Mr. Mark C. Johnson C.F.A. Vice President of Investor Relations NA
Mr. Michael J. Isaacs General Counsel & Corporate Secretary NA
Phillip Dolan Sr. Director & Head of Exploratory Research NA
Ms. Annie Evans Kingston Chief Strategy Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 14, 2025 William P Scully N/A Purchase 100.00K $12.79 $1.28M
Dec 31, 2024 William P Scully N/A Purchase 32.00K $13.01 $416.32K
Dec 20, 2024 William P Scully N/A Purchase 2.00K $15.91 $31.82K
Dec 18, 2024 William P Scully N/A Purchase 73.44K $13.93 $1.02M
Jan 24, 2024 Karin L. Walker N/A Sale 5.00K $34.00 $170.00K
Dec 20, 2023 Karin L. Walker N/A Sale 5.00K $37.19 $185.95K
Nov 30, 2023 Karin L. Walker N/A Sale 5.00K $34.00 $170.00K
Oct 25, 2023 Karin L. Walker N/A Sale 5.00K $41.04 $205.20K
Oct 11, 2023 Brandon S. Smith N/A Sale 4.00K $46.75 $187.00K
Oct 04, 2023 Carol D. Karp N/A Sale 5.00K $46.62 $233.10K
Sep 27, 2023 Michael J. Malecek N/A Sale 5.00K $47.38 $236.90K
Sep 19, 2023 Karin L. Walker N/A Sale 5.00K $52.36 $261.80K
Sep 13, 2023 Brandon S. Smith N/A Sale 4.00K $55.49 $221.96K
Sep 13, 2023 Hideki Garren N/A Sale 2.00K $55.48 $110.96K
Sep 06, 2023 Carol D. Karp N/A Sale 5.00K $54.76 $273.80K
Aug 30, 2023 Michael J. Malecek N/A Sale 5.00K $55.01 $275.05K
Aug 18, 2023 Karin L. Walker N/A Sale 5.00K $57.18 $285.90K
Aug 16, 2023 Hideki Garren N/A Sale 2.00K $58.74 $117.48K
Aug 16, 2023 Brandon S. Smith N/A Sale 4.00K $58.71 $234.84K
Aug 02, 2023 Wagner M. Zago N/A Sale 4.00K $67.05 $268.20K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 7.55M Mar 31, 2026 14.42% $0.00 0.00%
Rubric Capital Management LP 5.00M Mar 31, 2026 9.55% $0.51 35.97%
BlackRock Inc 4.64M Mar 31, 2026 8.87% $0.00 13.07%
Vanguard Group Inc 2.14M Dec 31, 2025 4.09% $0.00 4.44%
State Street Corp 1.94M Mar 31, 2026 3.70% $0.00 -14.52%
D. E. Shaw & Co LP 1.76M Mar 31, 2026 3.37% $0.01 4.88%
ADAR1 Capital Management LLC 1.58M Mar 31, 2026 3.02% $0.90 8.48%
Acadian Asset Management LLC 1.55M Mar 31, 2026 2.96% $0.02 1,457.72%
Vanguard Portfolio Management, LLC 1.45M Mar 31, 2026 2.76% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 1.23M Mar 31, 2026 2.35% $0.00 -1.31%
Palo Alto Investors, LLC 1.21M Mar 31, 2026 2.31% $1.80 -8.48%
Two Sigma Investments LLC 1.21M Mar 31, 2026 2.30% $0.01 79.96%
Geode Capital Management, LLC 1.10M Mar 31, 2026 2.10% $0.00 3.30%
Federated Hermes Inc 1.06M Mar 31, 2026 2.02% $0.02 8.77%
Jacobs Levy Equity Management, Inc. 972.02K Mar 31, 2026 1.86% $0.04 -0.61%
The Goldman Sachs Group Inc 818.89K Mar 31, 2026 1.56% $0.00 -12.45%
Dimensional Fund Advisors, Inc. 782.60K Mar 31, 2026 1.49% $0.00 0.95%
Nuveen, LLC 759.37K Mar 31, 2026 1.45% $0.00 0.03%
Qube Research & Technologies 614.60K Mar 31, 2026 1.17% $0.01 50.75%
Renaissance Technologies Corp 607.52K Mar 31, 2026 1.16% $0.01 39.49%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 3.43M 6.55% ▲ 0.04% May 31, 2026
2 Fidelity Growth Company Fund 2.29M 4.38% ▲ 0.00% May 31, 2026
3 State Street® SPDR® S&P® Biotech ETF 1.45M 2.77% ▼ 2.18% Jun 30, 2026
4 iShares Russell 2000 ETF 1.17M 2.24% ▲ 0.60% Jun 30, 2026
5 Fidelity Series Growth Company 758.91K 1.45% ▲ 0.00% May 31, 2026
6 Vanguard Explorer Inv 617.22K 1.18% ▲ 0.00% Mar 31, 2026
7 Fidelity Select Biotechnology 495.52K 0.95% ▲ 0.00% May 31, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 479.95K 0.92% ▲ 0.05% Jun 30, 2026
9 Nuveen Quant Small Cap Equity R6 451.23K 0.86% ▼ 30.81% May 31, 2026
10 Fidelity Small Cap Index 433.68K 0.83% ▲ 0.72% Apr 30, 2026

Financial Highlights

Market Cap: $448.14M
EBITDA: $-92.33M
PEG Ratio: $0.80
Book Value: $5.89
Earnings/Share: $-2.76
Profit Margin: -260.92%
Operating Margin: 50.49%
ROA (TTM): -13.78%
ROE (TTM): -40.30%
Revenue (TTM): $57.94M
Revenue/Share (TTM): $1.08
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 1,706.40%

Valuation Metrics

Enterprise Value: $133.67M
Trailing P/E: 0.00
Forward P/E: 10.63

Shares Statistics

Shares Outstanding: 52.35M
Shares Float: 36.68M
% Insiders: 2,018.20%
% Institutions: 9,075.90%
Short % Float: 18.78%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$9.68M
Cost of Goods Sold
adjust
$-3.70M
Gross Profit
subtotal
$5.98M
SG&A
adjust
$-59.39M
R&D
adjust
$-134.85M
Operating Income
subtotal
$-184.56M
Other / Non-Operating Items
adjust
$-59.53M
Net Income
subtotal
$-244.09M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PRTA.US!